Research ArticleFEATURED ARTICLE OF THE MONTH
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Marc Ingenwerth, Lukas Kessler, Kim M. Pabst, Francesco Barbato, Katharina Lueckerath, Stefan Kasper, Michael Nader, Hans-Ulrich Schildhaus, Claudia Kesch, Bastian von Tresckow, Christine Hanoun, Hubertus Hautzel, Clemens Aigner, Martin Glas, Martin Stuschke, Sherko Kümmel, Philipp Harter, Celine Lugnier, Waldemar Uhl, Marco Niedergethmann, Boris Hadaschik, Viktor Grünwald, Jens T. Siveke, Ken Herrmann and Wolfgang P. Fendler
Journal of Nuclear Medicine May 2023, 64 (5) 711-716; DOI: https://doi.org/10.2967/jnumed.122.264689
Nader Hirmas
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Rainer Hamacher
2Department of Medical Oncology, West German Cancer Center, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Miriam Sraieb
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Marc Ingenwerth
3Institute of Pathology, University Hospital Essen, Essen, Germany;
Lukas Kessler
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Kim M. Pabst
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Francesco Barbato
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Katharina Lueckerath
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Stefan Kasper
2Department of Medical Oncology, West German Cancer Center, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Michael Nader
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Hans-Ulrich Schildhaus
3Institute of Pathology, University Hospital Essen, Essen, Germany;
4Targos Molecular Pathology Inc., Kassel, Germany;
Claudia Kesch
5Department of Urology, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Bastian von Tresckow
6Department of Hematology and Stem Cell Transplantation, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Christine Hanoun
6Department of Hematology and Stem Cell Transplantation, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Hubertus Hautzel
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Clemens Aigner
7Department of Thoracic Surgery and Thoracic Endoscopy, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Martin Glas
8Division of Clinical Neurooncology, Department of Neurology, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Martin Stuschke
9Department of Radiation Therapy, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Sherko Kümmel
10Breast Unit, Kliniken Essen–Mitte, Essen, Germany, and Department of Gynecology with Breast Center, Charité–Universitätsmedizin Berlin, Berlin, Germany;
Philipp Harter
11Department of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen–Mitte, Essen, Germany;
Celine Lugnier
12Department of Hematology and Oncology with Palliative Care, Ruhr University Bochum, Bochum, Germany;
Waldemar Uhl
13Department of General and Visceral Surgery, Ruhr University Bochum, Bochum, Germany;
Marco Niedergethmann
14Clinic for General and Visceral Surgery, Alfried Krupp Hospital, Essen, Germany;
Boris Hadaschik
5Department of Urology, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Viktor Grünwald
5Department of Urology, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
Jens T. Siveke
15Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany; and
16Division of Solid Tumor Translational Oncology, DKTK (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany
Ken Herrmann
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Wolfgang P. Fendler
1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 64, Issue 5
May 1, 2023
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Marc Ingenwerth, Lukas Kessler, Kim M. Pabst, Francesco Barbato, Katharina Lueckerath, Stefan Kasper, Michael Nader, Hans-Ulrich Schildhaus, Claudia Kesch, Bastian von Tresckow, Christine Hanoun, Hubertus Hautzel, Clemens Aigner, Martin Glas, Martin Stuschke, Sherko Kümmel, Philipp Harter, Celine Lugnier, Waldemar Uhl, Marco Niedergethmann, Boris Hadaschik, Viktor Grünwald, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler
Journal of Nuclear Medicine May 2023, 64 (5) 711-716; DOI: 10.2967/jnumed.122.264689
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Marc Ingenwerth, Lukas Kessler, Kim M. Pabst, Francesco Barbato, Katharina Lueckerath, Stefan Kasper, Michael Nader, Hans-Ulrich Schildhaus, Claudia Kesch, Bastian von Tresckow, Christine Hanoun, Hubertus Hautzel, Clemens Aigner, Martin Glas, Martin Stuschke, Sherko Kümmel, Philipp Harter, Celine Lugnier, Waldemar Uhl, Marco Niedergethmann, Boris Hadaschik, Viktor Grünwald, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler
Journal of Nuclear Medicine May 2023, 64 (5) 711-716; DOI: 10.2967/jnumed.122.264689
Jump to section
Related Articles
Cited By...
- Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies
- Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma
- Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor
- Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future Perspectives
- Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
- Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial